Sarepta Therapeutics to Announce Third Quarter 2021 Financial Results and Recent Corporate Developments on November 3, 2021

Rhea-AI Summary

Sarepta Therapeutics (NASDAQ:SRPT) is set to report its third quarter 2021 financial results on November 3, 2021, after the market closes. A conference call will follow at 4:30 p.m. E.T. to discuss financial results and provide corporate updates. Investors can access the call by dialing (844) 534-7313 for domestic calls or (574) 990-1451 internationally, using passcode 7131019. The call will also be available via live webcast on the company's investor relations website and archived for 90 days.

Positive

• Scheduled conference call for Q3 2021 results allows for investor engagement.
• More than 40 programs in development indicates robust pipeline and growth potential.

Negative

• None.

CAMBRIDGE, Mass., Oct. 27, 2021 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report third quarter 2021 financial results after the Nasdaq Global Market closes on Wednesday, November 3, 2021. Subsequently, at 4:30 p.m. E.T., the Company will host a conference call to discuss its third quarter 2021 financial results and to provide a corporate update.

The conference call may be accessed by dialing (844) 534-7313 for domestic callers and (574) 990-1451 for international callers. The passcode for the call is 7131019. Please specify to the operator that you would like to join the "Sarepta Third Quarter 2021 Earnings Call." The conference call will be webcast live under the investor relations section of Sarepta.com and will be archived there following the call for 90 days. Please connect to Sarepta's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.

About Sarepta Therapeutics
Sarepta is on an urgent mission: engineer precision genetic medicine for rare diseases that devastate lives and cut futures short. We hold leadership positions in Duchenne muscular dystrophy (DMD) and limb-girdle muscular dystrophies (LGMDs), and we currently have more than 40 programs in various stages of development. Our vast pipeline is driven by our multi-platform Precision Genetic Medicine Engine in gene therapy, RNA and gene editing. For more information, please visit www.sarepta.com or follow us on Twitter, LinkedIn, Instagram and Facebook.

Internet Posting of Information
We routinely post information that may be important to investors in the 'For Investors' section of our website at www.sarepta.com. We encourage investors and potential investors to consult our website regularly for important information about us.

Source: Sarepta Therapeutics, Inc.

Investor Contact:
Ian Estepan, 617-274-4052
iestepan@sarepta.com

Media Contact:
Tracy Sorrentino, 617-301-8566
tsorrentino@sarepta.com

FAQ

When will Sarepta report its Q3 2021 financial results?

Sarepta will report its Q3 2021 financial results on November 3, 2021.

What time is the Sarepta Q3 2021 earnings call?

The earnings call is scheduled for 4:30 p.m. E.T. on November 3, 2021.

How can I access Sarepta's Q3 2021 earnings call?

You can access the call by dialing (844) 534-7313 for domestic callers or (574) 990-1451 for international callers, using passcode 7131019.

Is there a webcast for the Sarepta earnings call?

Yes, the conference call will be available via live webcast on the Sarepta investor relations website.

How long will the earnings call be archived?

The earnings call will be archived for 90 days on Sarepta's website.